Pharmacology  ·  Antiparkinson Drugs

Motor Complications of Long-Term Levodopa Therapy

Wearing-off, on-off fluctuations, dyskinesias, and management

• Motor complications emerge in the majority of patients after 5–10 years of levodopa therapy and are driven by two interacting factors: levodopa's short half-life and progressive loss of the dopamine-buffering capacity of surviving nigrostriatal neurons.
• Wearing-off is predictable — motor symptoms return at the end of each dose interval as plasma levodopa falls; it is managed by more frequent dosing, extended-release formulations, or adding adjunctive agents that prolong dopamine action.
• On-off fluctuations are unpredictable switches between mobile ("on") and immobile ("off") states, driven by pharmacokinetic instability and receptor changes; continuous dopaminergic delivery via dopamine agonists or intestinal infusion is the primary strategy.
• Dyskinesias are peak-dose involuntary choreiform movements caused by excess dopaminergic stimulation at the striatum — they are managed by reducing the individual levodopa dose, with amantadine (an NMDA antagonist) as the main antidyskinetic adjunct.
• The therapeutic challenge is that wearing-off and dyskinesias pull in opposite directions: increasing dose reduces wearing-off but worsens dyskinesias, while reducing dose does the reverse — continuous, smoother delivery is the ideal solution.